If you could vote on Brexit now which option would you choose?
   

Long Covid Is an Elusive Target for Big Pharma


Pharma companies do hold many assets worth testing. One example is Pfizer’s antiviral pill, Paxlovid. A growing body of research suggests that reservoirs of the virus remain in some people’s bodies beyond the acute phase, possibly leading to long Covid. A recent Harvard study showed that the spike protein from the virus lingered in the blood of 65% of the long Covid patients they tested for as long as 12 months after they were first diagnosed. “It’s a total game-changer. If we can measure this stuff, then we can test antiviral approaches to see if it helps,” says Steven Deeks, an HIV expert who is studying long Covid at the University of California, San Francisco. Dr. Deeks, like other researchers, has been calling on Pfizer to undertake a Paxlovid clinical trial for long Covid patients; yet a spokeswoman says the company is still “considering what a study may entail.”

The Wall Street Journal - July 10, 2022

View the full story here: https://www.wsj.com/articles/long-covid-is-an-elusive-target-for-big-pharma-11657473045